title: [Treatment of functional signs of acute maxillary rhinosinusitis in adults. Efficacy and tolerance of administration of oral prednisone for 3 days].
abstract: OBJECTIVE
  Acute maxillary rhinosinusitis (AMRS) is a pathology in which the pain is often severe and requires appropriate treatment. Although the use of antibiotics is widely documented, the interest of short cycles of corticosteroids in the treatment of the functional manifestations of AMRS is based on professional experience. The aim of this study was to assess the efficacy and tolerance to prednisone administered for 3 days in addition to antibiotherapy in patients presenting with an AMRS.
  
  
  METHODS
  This was a double blind, randomised study in parallel groups and controlled versus a placebo, involving patients aged over 18, presenting with an AMRS confirmed by X-ray and endoscopy, having developed less than 5 days and complaining of spontaneous pain assessed as >or=50 millimetres on a visual analog scale (VAS). Together with cefpodoxime, the patients received either prednisone (0.8 to 1.2 mg/kg) for 3 days or a placebo. The primary efficacy endpoint was the mean of the differences versus the baseline value of pain (MPID - mean pain intensity difference) assessed on the VAS from Day 1 to Day 3. The secondary endpoints assessed were the mean of the differences in intensity of nasal obstruction, assessed in the same way as the MPID, the time lapse before the orally expressed relief of the pain (PRID - pain reflief intensity difference) and the administration of paracetamol during the first 3 days.
  
  
  RESULTS
  289 patients (placebo 147, prednisone 142) were assessable for analysis in intent-to-treat (ITT). The global spontaneous pain on inclusion, measured by a VAS was of 73.0 +/- 14.1 mm. The assessments made during the first 3 days of treatment showed a statistically significant difference in favour of the prednisone group regarding MPID: - 4.82 mm (CI 95% -9.25; -0.40) (p=0.03), nasal obstruction - 5.0 mm (CI 95% -9.1; -0.8) (p=0.02) and consumption of paracetamol (p=0.03). There was no difference between the two groups after the end of the antibiotherapy. The tolerance measured throughout the study was comparable between the two groups.
  
  
  CONCLUSIONS
  This study clearly showed the efficacy of a short course of oral prednisone (3 days), versus a placebo, in the treatment of the functional signs of acute maxillary rhinosinusitis with severe pain in adults in addition to an appropriate antibiotic treatment.
authors.affiliation: Service ORL, Hôpital Jean Bernard la Miléterie, Poitiers. j.m.klossek@chu-poitiers.fr
authors.forename: J-M
authors.initials: JM
authors.lastname: Klossek
authors.forename: C
authors.initials: C
authors.lastname: Desmonts-Gohler
authors.forename: B
authors.initials: B
authors.lastname: Deslandes
authors.forename: F
authors.initials: F
authors.lastname: Coriat
authors.forename: P
authors.initials: P
authors.lastname: Bordure
authors.forename: C
authors.initials: C
authors.lastname: Dubreuil
authors.forename: P
authors.initials: P
authors.lastname: Gehanno
authors.forename: L
authors.initials: L
authors.lastname: Gilain
authors.forename: R
authors.initials: R
authors.lastname: Jankowski
authors.forename: E
authors.initials: E
authors.lastname: Serrano
authors.forename: D
authors.initials: D
authors.lastname: Stoll
mesh_terms: D000082:Acetaminophen / Q000009:adverse effects / Q000627:therapeutic use; D000284:Administration, Oral; D000328:Adult; D018712:Analgesics, Non-Narcotic / Q000009:adverse effects / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015296:Ceftizoxime / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D015523:Maxillary Sinusitis / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D015508:Nasal Obstruction / Q000188:drug therapy / Q000209:etiology; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D010147:Pain Measurement; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012220:Rhinitis / Q000188:drug therapy*; D016896:Treatment Outcome; D000097623:Cefpodoxime
chemical_list: D000082:Acetaminophen; D018712:Analgesics, Non-Narcotic; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D015296:Ceftizoxime; D011241:Prednisone; D000097623:Cefpodoxime